Elevated Myostatin Levels in Patients with Liver Disease
2010; Lippincott Williams & Wilkins; Volume: 111; Issue: 3 Linguagem: Inglês
10.1213/ane.0b013e3181eac1c9
ISSN1526-7598
AutoresPaul S. García, Amy Cabbabe, Ravi Kambadur, G. Nicholas, Marie Csete,
Tópico(s)GDF15 and Related Biomarkers
ResumoIn Brief Loss of skeletal muscle mass is a poorly understood complication of end-stage liver disease (ESLD). Based on recent stem cell literature, we hypothesized that the potent negative regulator of muscle mass, myostatin, could play a role in the muscle loss associated with ESLD. In this preliminary investigation, we measured myostatin levels in patients undergoing liver transplant evaluation, using a novel enzyme-linked immunosensitivity assay. Myostatin levels were significantly elevated in patients with ESLD compared with healthy controls. These data suggest that myostatin deserves further investigation as a target for therapies designed to preserve muscle mass in patients with ESLD. Published ahead of print August 4, 2010
Referência(s)